Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
106
-
Total 13F shares, excl. options
-
53.7M
-
Shares change
-
+7.38M
-
Total reported value, excl. options
-
$125M
-
Value change
-
+$17.7M
-
Put/Call ratio
-
0.57
-
Number of buys
-
54
-
Number of sells
-
-47
-
Price
-
$2.33
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2022
141 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q4 2022.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 106 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 53.7M shares
of 193M outstanding shares and own 27.78% of the company stock.
Largest 10 shareholders include BlackRock Inc. (8.7M shares), Two Seas Capital LP (7.5M shares), VANGUARD GROUP INC (5.37M shares), Hudson Bay Capital Management LP (4.85M shares), Whitefort Capital Management, LP (3.85M shares), Rubric Capital Management LP (3.47M shares), GEODE CAPITAL MANAGEMENT, LLC (2.13M shares), STATE STREET CORP (2.03M shares), FourWorld Capital Management LLC (2M shares), and MILLENNIUM MANAGEMENT LLC (1.85M shares).
This table shows the top 106 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.